Comparison of Two Survival Curves

Slides:



Advertisements
Similar presentations
Agency for Healthcare Research and Quality (AHRQ)
Advertisements

Surviving Survival Analysis
Survival Analysis. Key variable = time until some event time from treatment to death time for a fracture to heal time from surgery to relapse.
Survival Analysis In many medical studies, the primary endpoint is time until an event occurs (e.g. death, remission) Data are typically subject to censoring.
Survival Analysis-1 In Survival Analysis the outcome of interest is time to an event In Survival Analysis the outcome of interest is time to an event The.
April 25 Exam April 27 (bring calculator with exp) Cox-Regression
بسم الله الرحمن الرحیم. Generally,survival analysis is a collection of statistical procedures for data analysis for which the outcome variable of.
Lecture 3 Survival analysis. Problem Do patients survive longer after treatment A than after treatment B? Possible solutions: –ANOVA on mean survival.
Survival analysis1 Every achievement originates from the seed of determination.
PH6415 Review Questions. 2 Question 1 A journal article reports a 95%CI for the relative risk (RR) of an event (treatment versus control as (0.55, 0.97).
Chapter 11 Survival Analysis Part 2. 2 Survival Analysis and Regression Combine lots of information Combine lots of information Look at several variables.
Introduction to Survival Analysis PROC LIFETEST and Survival Curves.
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
Sample Size Determination Ziad Taib March 7, 2014.
Survival Analysis A Brief Introduction Survival Function, Hazard Function In many medical studies, the primary endpoint is time until an event.
Analysis of Complex Survey Data
Kaplan-Meier Estimation &Log-Rank Test Survival of Ventilated and Control Flies (Old Falmouth Line 107) R.Pearl and S.L. Parker (1922). “Experimental Studies.
Survival analysis Brian Healy, PhD. Previous classes Regression Regression –Linear regression –Multiple regression –Logistic regression.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 10: Survival Curves Marshall University Genomics Core.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
NASSER DAVARZANI DEPARTMENT OF KNOWLEDGE ENGINEERING MAASTRICHT UNIVERSITY, 6200 MAASTRICHT, THE NETHERLANDS 22 OCTOBER 2012 Introduction to Survival Analysis.
HSRP 734: Advanced Statistical Methods July 10, 2008.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
Lecture 3 Survival analysis.
Statistical approaches to analyse interval-censored data in a confirmatory trial Margareta Puu, AstraZeneca Mölndal 26 April 2006.
Prevalence The presence (proportion) of disease or condition in a population (generally irrespective of the duration of the disease) Prevalence: Quantifies.
03/20141 EPI 5344: Survival Analysis in Epidemiology Log-rank vs. Mantel-Hanzel testing Dr. N. Birkett, Department of Epidemiology & Community Medicine,
INTRODUCTION TO SURVIVAL ANALYSIS
Chapter 12 Survival Analysis.
01/20151 EPI 5344: Survival Analysis in Epidemiology Survival curve comparison (non-regression methods) March 3, 2015 Dr. N. Birkett, School of Epidemiology,
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Censoring an observation of a survival r.v. is censored if we don’t know the survival time exactly. usually there are 3 possible reasons for censoring.
Please turn off cell phones, pagers, etc. The lecture will begin shortly.
Introduction Sample Size Calculation for Comparing Strategies in Two-Stage Randomizations with Censored Data Zhiguo Li and Susan Murphy Institute for Social.
01/20151 EPI 5344: Survival Analysis in Epidemiology Actuarial and Kaplan-Meier methods February 24, 2015 Dr. N. Birkett, School of Epidemiology, Public.
Some survival basics Developments from the Kaplan-Meier method October
Hazlina Hamdan 31 March Modelling survival prediction in medical data By Hazlina Hamdan Dr. Jon Garibaldi.
Topic 19: Survival Analysis T = Time until an event occurs. Events are, e.g., death, disease recurrence or relapse, infection, pregnancy.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 13: Multiple, Logistic and Proportional Hazards Regression.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Time to Initiation of Adjuvant.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
1 Analysis of Survival Data with Demographic Applications (Spring term 2006) Lecture 3: Non-Parametric Comparison of two or more Survival Curves.
Carolinas Medical Center, Charlotte, NC Website:
From: Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseThe REDUCE Randomized Clinical Trial.
April 18 Intro to survival analysis Le 11.1 – 11.2
Survival Analysis Rick Chappell, Ph.D. Professor,
Survival curves We know how to compute survival curves if everyone reaches the endpoint so there is no “censored” data. Survival at t = S(t) = number still.
Survival Analysis: From Square One to Square Two Yin Bun Cheung, Ph.D. Paul Yip, Ph.D. Readings.
Compassionate People World Class Care
Copyright © 2014 American Medical Association. All rights reserved.
Statistics.
Statistical Inference for more than two groups
Statistics in medicine
1 Chapter 1: Introduction to Statistics. 2 Variables A variable is a characteristic or condition that can change or take on different values. Most research.
Survival Analysis with STATA
Copyright © 2013 American Medical Association. All rights reserved.
Statistics 103 Monday, July 10, 2017.
Saturday, August 06, 2016 Farrokh Alemi, PhD.
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
Baseline Characteristics of the Subjects
Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.
Where are we?.
Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.
Sample Size and Power Part II
Comparison of Baseline Characteristics by Primary End Point
Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.
Kaplan-Meier survival curves and the log rank test
(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.
Cumulative probability of CIN2 stratified by HPV test results.
Presentation transcript:

Comparison of Two Survival Curves Landmark comparison at a pre-specified time t: divide S^T(t) – S^C(t) by the standard error of the difference computed using Greenwood’s estimator. See “Point-byPoint” Comparisons, p. 329 of FFDRG.

Comparison of Two Survival Curves 2. Restricted mean survival time (= RM life) at time t: Mean survival up to time t; = Mean[min(t, survival time)] = Area under S^(.) between 0 and t. Interpreted as “Mean number of years lived out of t” Not “Mean number of years lived given death before t”: what is the RMST(5 years) for US newborns? Can also be added & subtracted, as with unrestricted means, e.g.: RMOverallSurvivalT(3 years) = RMTto recurrence(3) + RMTfromRecurrencetoDeath(3)

Comparison of Two Survival Curves 2. Restricted mean survival time (cont.): Not in FFDRG, but see Uno, et al., “Alternatives to hazard ratios for comparing efficacy or safety of therapies in noninferiority studies.” Ann Intern Med. 163, pp. 127-134: 2015 for references and examples in diabetes and colorectal cancer. See Glasziou, Simes, & Gelber, Stat. in Med. 9, 1259-1276: 1990 for an example in breast cancer. For short description of general considerations, see Chappell & Zhu, “Describing differences in survival curves.” JAMA Onc., published online 4/28/2016.

Comparison of Two Survival Curves 3. Mantel-Haenszel (Log-rank) Test Ref: Mantel & Haenszel (1959) J Natl Cancer Inst Mantel (1966) Cancer Chemotherapy Reports - Mantel and Haenszel (1959) showed that a series of 2 x 2 tables could be combined into a summary statistic, based on the work of Cochran and Cox. - Mantel (1966) applied this procedure to the comparison of two survival curves. - Basic idea is to form a 2 x 2 table at each distinct death time, determining the number in each group who were at risk and number who died.

Suppose we have K distinct times for a death occurring at tj j = 1,2, .., K. For each death time tj, we have a table such as on p. 330 of FFDRG. They use standard “contingency table notation”. To translate into “survival analysis notation”: DjI = # of deaths at time tj in Intervention group = aj DjC = # of deaths at time tj in Control group = cj RjI = # at risk at time tj in Intervention group = aj + bj RjC = # at risk at time tj in Control group = cj + dj . Consider aj, the observed number of deaths in the TRT group, under H0

Mantel-Haenszel Statistic E(aj) = (aj + bj)(aj + cj)/Ni Mantel-Haenszel Statistic

Table 15.3: Comparison of Survival Data for a Control Group and an Intervention Group Using the Mantel-Haenszel Procedure Rank Event Intervention Control Total Times j tj aj + bj aj lj cj + dj cj lj aj + cj bj + dj 1 0.5 20 0 0 20 1 1 1 39 2 1.0 20 1 0 18 0 0 1 37 3 1.5 19 0 2 18 2 1 2 35 4 3.0 17 0 1 15 1 2 1 31 5 4.5 16 1 0 12 0 0 1 27 6 4.8 15 0 1 12 1 0 1 26 7 6.2 14 0 1 11 1 2 1 24 8 10.5 13 0 1 8 1 1 20 aj + bj = number of subjects at risk in the intervention group prior to the death at time tj cj + cj = number of subjects at risk in the control group prior to the death at time tj aj = number of subjects in the intervention group who died at time tj cj = number of subjects in the control group who died at time tj lj = number of subjects who were lost or censored between time tj and time tj+1 aj + cj = number of subjects in both groups who died at time tj bj + dj = number of subjects in both groups who are at risk minus the number who died at time tj

Mantel-Haenszel Test Operationally 1. Rank event times for both groups combined 2. For each failure, form the 2 x 2 table a. Number at risk (ai + bi, ci + di) b. Number of deaths (ai, ci) c. Losses (lTi, lCi) Example (See table 15-3 FFDRG) - Use previous data set Trt: 1.0, 1.6+, 2.4+, 4.2+, 4.5, 5.8+, 7.0+, 11.0+, 12.0+'s Control: 0.5, 0.6+, 1.5, 1.5, 2.0+, 3.0, 3.5+, 4.0+, 4.8, 6.2, 8.5+, 9.0+, 10.5, 12.0+'s

2. At t1 = 0.5 (k = 1) 1. Ranked Failure Times - Both groups combined 0.5, 1.0, 1.5, 3.0, 4.5, 4.8, 6.2, 10.5 C T C C T C C C 8 distinct times for death (k = 8) 2. At t1 = 0.5 (k = 1) T: a1 + b1 = 20 a1 = 0 lT1 = 0 c1 + d1 = 20 c1 = 1 lC1 = 1 D A R T 0 20 20 C 1 19 20 1 39 40 E(a1)= 1•20/40 = 0.5 V(a1) = 1•39 • 20 • 20 402 •39

3. At t2 = 1.0 (k = 2) T: a2 + b2 = (a1 + b1) - a1 - lT1 a2 = 1.0 = 20 - 0 - 0 = 20 lT2 = 3 C. c2 + d2 = (c1 + d1) - c1 - lC1 c2 = 0 = 20 - 1 - 1 = 18 lC2 = 0 so D A R T 1 19 20 C 0 18 18 1 37 38 E(a2)= 1•20 38 V(a2) = 1•37 • 20 • 18 382 •37

Eight 2x2 Tables Corresponding to the Event Times Used in the Mantel-Haenszel Statistic in Survival Comparison of Treatment (T) and Control (C) Groups 1. (0.5 mo.)* D† A‡ R§ 5. (4.5 mo.)* D A R T 0 20 20 T 1 15 16 C 1 19 20 C 0 12 12 1 39 40 1 27 28 2. (1.0 mo) D A R 6. (4.8 mo.) D A R T 1 19 20 T 0 15 15 C 0 18 18 C 1 11 12 1 37 38 1 26 27 3. (1.5 mo.) D A R 7. (6.2 mo.) D A R T 0 19 19 T 0 14 14 C 2 16 18 C 1 10 11 2 35 37 1 24 25 4. (3.0 mo.) D A R 8. (10.5 mo.) D A R T 0 17 17 T 0 13 13 C 1 14 15 C 1 7 8 1 31 32 1 20 21 * Number in parentheses indicates time, tj, of a death in either group † Number of subjects who died at time tj ‡ Number of subjects who are alive between time tj and time tj+1 § Number of subjects who were at risk before the death at time tj R=D+A)

Compute MH Statistics Recall K = 1 K = 2 K = 3 t1 = 0.5 t2 = 1.0 t3 = 1.5 D A 0 20 20 1 19 20 1 39 40 D A 1 19 20 0 18 18 1 37 38 D A 0 19 19 2 16 18 2 35 37 a. ai = 2 (only two treatment deaths) b. E(ai ) = 20(1)/40 + 20(1)/38 + 19(2)/37 + . . . = 4.89 c. V(ai) = = 2.22 d. MH = (2 - 4.89)2/2.22 = 3.76 or ZMH =

Comparison of Two Survival Curves 4. Peto (old-fashioned version: Gehan) modification of the Wilcoxon Test to account for censored data. Derived as a modification of the Wilcoxon two-sample rank test. Equivalent to a weighted MH (logrank) test, with the weight at time tj = S^(tj), the Kaplan-Meier curve for the combined sample. When would we want to use decreasing weights? When (if ever) would we want to use increasing weights?